For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | - | - | 5,080 | 5,336 |
| General and administrative | - | - | 967 | 1,000 |
| Total operating expenses | - | - | 6,047 | 6,336 |
| Loss from operations | -6,274 | -37,110* | -6,047 | -6,336 |
| Interest income | 914 | 1,244* | 1,427 | 1,530 |
| Interest expense | 0 | -88* | 0 | 0 |
| Other expense | 1,036 | 1,589* | -85 | -3 |
| Foreign exchange (loss) gain | -1,132 | 513* | -1,201 | 3,081 |
| Total other income | 818 | 3,257* | 141 | 4,608 |
| Income before income taxes | -5,456 | -33,854* | -5,906 | -1,728 |
| Income tax expense | 49 | 40* | 102 | 28 |
| Net loss | -5,505 | -33,894 | -6,008 | -1,756 |
| Basic EPS | -0.18 | -1.112 | -0.2 | -0.06 |
| Diluted EPS | - | -1.112 | - | - |
| Basic Average Shares | 30,487,731 | 30,487,731 | 30,487,731 | 30,487,731 |
| Diluted Average Shares | - | 30,487,731 | - | - |
XBiotech Inc. (XBIT)
XBiotech Inc. (XBIT)